

Drug Implants Help Reduce Opioid Dependence

BY MARY ANN MOON

FROM JAMA

Buprenorphine implants helped approximately 40% of patients addicted to opioids markedly reduce their drug use for 6 months in a phase III study of this new method of delivery.

In addition, two-thirds of the study subjects who received the implants completed 24 weeks of treatment without ex-

periencing cravings or withdrawal symptoms compelling them to drop out, said Dr. Walter Ling of the UCLA Integrated Substance Abuse Programs, Los Angeles, and his associates.

In comparison, studies of sublingual buprenorphine found a median adherence of only 40 days in clinical settings, and 6-month clinical trials report subject retention rates of 35%-38%, the investigators noted.

The implantable formulation of buprenorphine was developed to address dependent patients' problems with adherence and "diversion," or using the drug for some purpose other than treatment, such as selling it. The implants deliver an initial pulse of buprenorphine followed by the release of a constant, low level for 6 months.

Dr. Ling and his colleagues performed their industry-sponsored phase III study

at 18 community addiction treatment centers across the United States. In all, 108 subjects were randomly assigned to receive four buprenorphine implants and 55 to receive four placebo implants in the subdermal space in the inner side of the nondominant arm.

The study subjects were allowed to receive supplemental sublingual buprenorphine-plus-naloxone tablets if they experienced significant withdrawal

FDA Okays Long-Acting Naltrexone

The injectable extended-release formulation of naltrexone, marketed as Vivitrol, has been approved as a treatment for preventing relapses in people who have undergone opioid detoxification, the Food and Drug Administration announced.

Vivitrol, which was approved in 2006 for the treatment of alcohol dependence, is administered in an intramuscular injection once a month, in patients who have no opioids remaining in their system.

If opioids are present, patients may experience withdrawal symptoms, according to the FDA statement. Naltrexone is an opioid antagonist.

Approval was based on the results of a 6-month study of 250 patients who were completing or had recently completed detoxification and were no longer physically dependent on opioids.

Between the 5th week and the end of the study, 36% of those treated with Vivitrol (one 380-mg injection once a month) had not used opioids at all, compared with 23% of those on placebo, a significant difference. All patients received psychosocial support during the study.

Side effects associated with Vivitrol treatment include nausea, fatigue, headache, dizziness, vomiting, reduced appetite, painful joints, and muscle cramps, the FDA statement said.

Serious side effects include injection site reactions, allergic reactions, hepatotoxicity, and depression, as well as suicidal thoughts and behavior.

Customized needles provided in the Vivitrol package must be used to inject the medication as an intramuscular gluteal injection, according to the FDA and Alkermes Inc., the manufacturer of Vivitrol.

The FDA has asked the company to conduct postmarketing pharmacokinetic and efficacy studies of Vivitrol in patients aged 12-16 years.

Serious adverse reactions associated with Vivitrol should be reported to the FDA's MedWatch program at 800-332-1088 or www.fda.gov/medwatch.

—Elizabeth Mechatie

Easy to teach¹

—Can be used in 6 straightforward steps

Easy to use¹

—Only long-acting insulin pen in which dose can be set from 1 to 80 units in 1-unit steps, dialed both up and down

—Once opened, Lantus[®] SoloSTAR[®] can be used for up to 28 days and is not refrigerated

Easy to inject¹

—Dose cannot be dialed past the number of units left in the pen

—It is important to keep the injection button pressed all the way in and to **slowly count to 10 before withdrawing the needle from the skin**. After a full injection, the number in the dose window will return to zero. These steps help ensure that the full dose has been delivered

—To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose

Important Safety Information for Lantus[®]

Contraindications

Lantus[®] is contraindicated in patients hypersensitive to insulin glargine or one of its excipients.

Warnings and precautions

Monitor blood glucose in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment.

Do not dilute or mix Lantus[®] with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Lantus[®] via an insulin pump or intravenously because severe hypoglycemia can occur. Insulin devices and needles must not be shared between patients.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Lantus[®], and may be life-threatening.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur.

A reduction in the Lantus[®] dose may be required in patients with renal or hepatic impairment.

Drug interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (e.g., beta-blockers, clonidine, guanethidine, and reserpine).

Adverse reactions

Other adverse reactions commonly associated with Lantus[®] are injection site reaction, lipodystrophy, pruritus, and rash.

Indications and Usage for Lantus[®]

Lantus[®] is a long-acting insulin analog indicated to improve glycemic control in adults and children (6 years and older) with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Lantus[®] should be administered once a day at the same time every day.

Important Limitations of Use: Lantus[®] is not recommended for the treatment of diabetic ketoacidosis. Use intravenous short-acting insulin instead.

Lantus[®] SoloSTAR[®] is a disposable prefilled insulin pen.

Please see brief summary of full prescribing information for Lantus[®] on the next page.

References: 1. Data on file, sanofi-aventis U.S. LLC. 2. Lantus Prescribing Information. September 2009.

VITALS

Major Finding: Among patients addicted to opioids, 40% were able to discontinue illicit drug use for 4 months and 37% for 6 months after receiving buprenorphine implants, while only 28% and 22%, respectively, discontinued illicit drug use after receiving placebo implants.

Data Source: A phase III, randomized placebo-controlled trial of 163 patients treated at 18 U.S. clinical centers and followed for 6 months.

Disclosures: This study was funded by Titan Pharmaceuticals, maker of the buprenorphine implants, which was involved in the design and management of the study, data collection and analysis, and preparation and approval of the manuscript. Dr. Ling and his associates reported numerous ties to drug and device manufacturers.

symptoms or cravings. They also were allowed to get one additional implant if necessary. All also received individual drug counseling twice a week for 3

months and weekly thereafter.

The patients' use of illicit drugs was monitored throughout the study by urinalyses done 3 times per week.

the placebo implants, the researchers said (JAMA 2010;304:1576-83).

For the full 6-month treatment period, in which 72 urine samples were analyzed

for each subject, 37% were negative for illicit opioids in the buprenorphine group, compared with 22% for placebo.

Treatment adherence was significantly better with the active treatment at 16 weeks (82% with buprenorphine vs. 51% with placebo) and at the conclusion of the study (66% vs. 31%). Throughout the study, the implant group also had significantly lower scores on measures of opiate withdrawal and opioid craving. No patients who received buprenorphine implants were classified as treatment failures, while 31% who received placebo implants were. ■

For patients with diabetes using an insulin vial and syringe

Take aim with the Lantus® SoloSTAR® pen

Delivers 50% more insulin units per prescription for the same co-pay as a vial and syringe on most insurance plans

Prefilled with Lantus®, the only 24-hour insulin approved exclusively for use once a day to help patients with diabetes aim toward glycemic control²

Once-Daily 24-HOUR
LANTUS® SoloSTAR®
 insulin glargine [rDNA origin] injection
STARring the #1-prescribed insulin^a

^aBased on TRx data from IMS Health, NPA™ Monthly database, time period from May 2003 to March 2010.

sanofi aventis
 Because health matters

© 2010 sanofi-aventis U.S. LLC US.GLA.10.05.140